L'Oréal posts sales growth with signs of China demand recovery; share rise

L'Oréal shares rose approximately 4% after the French cosmetics giant reported a 3% increase in H1 2025 like-for-like sales and a 1% rise in net profit to €3.78 billion. The positive results were driven by early signs of recovery in mainland China, with Q2 sales up 3% following a Q1 decline, alongside improving trends in the U.S. and strong double-digit growth in emerging markets. Despite these gains, currency headwinds reduced H1 sales by 1.9%, with a projected 3.7% full-year drag, though L'Oréal anticipates continued global beauty market improvement in the second half.

Analysis

L'Oréal (OREP) shares advanced approximately 4% following its first-half 2025 results, which signaled a notable operational recovery despite significant currency pressures. The company reported a 3% increase in like-for-like sales and a 1% rise in net profit to €3.78 billion. A key driver for this performance was the turnaround in mainland China, where sales growth reversed from a slight first-quarter decline to a 3% increase in the second quarter, complemented by improving trends in the U.S. market. Furthermore, emerging markets served as a primary growth engine, delivering double-digit expansion. However, these operational gains were partially offset by adverse currency movements, which reduced H1 sales by 1.9% and are projected to create a 3.7% drag for the full year. Analyst commentary from Morgan Stanley suggests that the full impact of strong U.S. consumer data may not yet be reflected in results, potentially pointing to further organic sales growth in the third quarter. While the company maintains an optimistic outlook for the global beauty market in the second half, the article also subtly questions the stock's valuation, suggesting it may not be considered deeply undervalued.

Key Decisions for Investors

• Investors should weigh the positive underlying business momentum, particularly the recovery in China and strength in emerging markets, against the significant and ongoing currency headwinds that are dampening reported results.
• Monitor upcoming Q3 results closely for confirmation of accelerated organic growth, especially from the U.S. market, as suggested by analyst commentary, which could act as a key near-term catalyst.
• Given the recent share price appreciation and the article's note on valuation, it is prudent to assess the risk-reward profile and avoid chasing the rally without considering if the current price fully reflects the operational improvements.